$6.960
-0.287 (-4.13%)At close
DNA News
DNA Events
Ginkgo Bioworks Reaffirms 2026 Expected Cash Burn of $150M-$125M
Ginkgo Bioworks reaffirms 2026 expected total cash burn of ($150M)-($125M)
Ginkgo Reports Q1 Revenue of $19.47M, Below Expectations
Reports Q1 revenue $19.47M, consensus $42.96M. "We believe autonomous labs will replace the lab bench more quickly than people think," said Jason Kelly, CEO. "Nebula is already the world's largest autonomous lab with the ability to run real customer science around the clock and we're targeting to double its size this year. We see a large market that remains overwhelmingly manual today, and every experiment our Solutions, Datapoints, and Cloud Lab businesses run on Nebula generates revenue today while making the platform better for tomorrow. Ginkgo is singularly focused on leading the transition from the lab bench to autonomous research infrastructure that runs 24/7 and integrates directly with the AI models transforming drug discovery and industrial biotechnology."
Ginkgo Bioworks Reports Q4 Net Loss of $81M
Reports Q4 GAAP net loss of ($81M) compared to ($108M) in the comparable prior year period . "This year, we are going to focus on investing to win in the category of autonomous labs," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "There is an emerging wave of interest in robotics and AI, and our work with the Department of Energy and OpenAI this year shows that Ginkgo is in the best position to bring robotics to an extraordinarily high value area: laboratory research."
Ginkgo Reaches Agreement to Sell Biosecurity Business
Ginkgo announced it has reached an agreement to sell the company's biosecurity business to a consortium of investors in exchange for a minority equity position in the business alongside the Investors. Upon completion, the biosecurity business will operate as a standalone private entity focused on building a scaled, biosecurity infrastructure platform for the United States and its global partners. The transaction provides the biosecurity business with greater flexibility and additional resources to pursue near- and long-term growth opportunities. Per Ginkgo CEO Jason Kelly, "There is rising interest in defense tech in private capital markets and spinning off our biosecurity business into a private entity with new investors allows it to grow faster with more investment than it would inside Ginkgo. This serves Ginkgo in two ways: we are able to participate in the upside of the new entity as a shareholder but importantly we also focus Ginkgo's cash investment on our autonomous labs business." Ginkgo expects to complete the transaction in the first half of 2026, subject to the satisfaction of customary closing conditions.
Ginkgo Bioworks Expects Total Cash Burn of $150M-$125M in 2026
Ginkgo Bioworks expects total cash burn of ($150M)-($125M) in 2026
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.